Angela E Frimberger
Overview
Explore the profile of Angela E Frimberger including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moore A, Frimberger A, Taylor D, Sullivan N
Vet Comp Oncol
. 2020 Jan;
18(3):402-408.
PMID: 31916687
Published outcomes for dogs with specifically high-grade mast cell tumours (MCTs), controlled for clinical stage, are few. Clinical outcomes for 49 dogs with Kiupel high-grade, clinical stage I, cutaneous MCTs...
2.
Long A, Javsicas L, Stokol T, Felippe M, Frimberger A
J Am Vet Med Assoc
. 2019 Sep;
255(6):716-721.
PMID: 31478818
Case Description: A 17-year-old Friesian gelding was examined at a referral hospital because of a 1-month history of mild exercise intolerance and marked lymphocytosis. Clinical Findings: Physical examination revealed no...
3.
Luethy D, Frimberger A, Bedenice D, Byrne B, Groover E, Gardner R, et al.
J Vet Intern Med
. 2019 Jan;
33(2):953-960.
PMID: 30636061
Background: Prognosis associated with lymphoma in horses is poorly characterized, and treatment is often palliative. Long-term outcome after chemotherapy for horses with lymphoma is not well documented. Objective: To report...
4.
Smith A, Frimberger A, Moore A
J Am Vet Med Assoc
. 2019 Jan;
254(2):243-250.
PMID: 30605388
OBJECTIVE To estimate survival time for dogs with small intestinal adenocarcinoma (SIACA) following tumor excision with or without adjuvant chemotherapy and to identify factors associated with survival time. DESIGN Retrospective...
5.
Moore A, Frimberger A
J Am Vet Med Assoc
. 2018 Mar;
252(7):852-859.
PMID: 29553895
OBJECTIVE To evaluate factors for associations with duration of first remission and survival time in dogs ≥ 14 years of age with stage III to V multicentric lymphoma. DESIGN Retrospective...
6.
Chan C, Frimberger A, Moore A
Vet Dermatol
. 2017 Oct;
29(2):154-e59.
PMID: 28983988
Background: Limited information is available regarding the treatment and outcome of dogs with epitheliotropic lymphoma. The disease typically has a poor prognosis. Objectives: To characterize the clinical signs, identify prognostic...
7.
Moore A, Rassnick K, Frimberger A
J Am Vet Med Assoc
. 2017 Aug;
251(5):559-565.
PMID: 28828962
OBJECTIVE To determine histologic and clinical factors associated with survival time in dogs with stage II splenic hemangiosarcoma treated by splenectomy and a chemotherapy protocol in which an anthracycline was...
8.
Best M, Frimberger A
Can Vet J
. 2017 May;
58(5):493-497.
PMID: 28487593
A 3-year-old Weimaraner dog was presented with bilateral papillary ovarian carcinoma and abdominal carcinomatosis. Treatment included ovariectomy, intraperitoneal cisplatin, and systemic carboplatin. Pleural carcinomatosis 473 days following surgery was treated...
9.
Chan C, Frimberger A, Moore A
J Am Vet Med Assoc
. 2016 Dec;
249(12):1408-1414.
PMID: 27901449
OBJECTIVE To determine the incidence of sterile hemorrhagic cystitis (SHC) in tumor-bearing dogs concurrently treated with oral metronomic cyclophosphamide chemotherapy and furosemide. DESIGN Retrospective case series. ANIMALS 55 dogs. PROCEDURES...
10.
Goodman I, Moore A, Frimberger A
Vet J
. 2016 Mar;
211:39-44.
PMID: 27017053
The immunophenotype of canine non-indolent lymphoma has prognostic value; dogs with T cell lymphoma have a poorer response rate and shorter survival times than dogs with B cell lymphoma. This...